Phase II trial of merbarone in patients with malignant brain tumors

Medical Oncology

Volumn 14, Issue 3-4, 1997, Pages 159-162

  Malik, Ummekalsoom R ^a,b   Dutcher, Janice P ^a   Caliendo, Geralyn ^a   Lasala, Patrick ^a   Mitnick, Robin ^a   Wiernik, Peter H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Brain tumor; Glioblastoma multiforme; Merbarone

Indexed keywords

MERBARONE;

ADULT; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; GLIOBLASTOMA; HUMAN; HYPOURICEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOPHLEBITIS; TREATMENT FAILURE;

EID: 0031470996     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02989644     Document Type: Article

References (12)

1. Cooney, D.A., Covey, J.M., Knag, G.J., Dalal, M., McMahon, J.F. and Johns, D.G. (1985) Initial echanistic studies with merbarone (NSC#336628). Biochem. Pharmacol. 34, 3395-8.
2. Cooney, D.A., Covey, J.M., Dalal, M., Plownan, J., Kensler, T.W., Sinha, B. and Johns, D.G. (1986) Mechanistic studies with merbarone. Proc. Am. Assoc. Cancer Res. 27, 276 (Abstract 1093).
3. Johnson, R.K., Hofman, G.A., Bartus, H.F., Mattern, M.R., Bartus, J.O., Mong, S.M. and Mirabelli, C.K. (1988) Inhibition of topoisomerase II by merbarone. Proc. Am. Assoc. Cancer Res. 29, (Abstract 1304).
4. Brewer, A.D., Minatelli, J.A., Plowman, J., Paull, K.D. and Narayanan, V.L. (1985) 5-(N-phyenyl carboxamido) thiobarbituric acid (NSC 336628). A novel potential anti-tumor agent. Biochemical. Pharmacol. 34, 2047-50.
5. Glover, A., Chun, H.G., Kleinman, L.M., Cooney, D.A., Plowman, J.M., Gieshaber, C.K., Maispeis, L. and Leyland, J.B. (1987) Merbarone an anti tumor agent entering clinical trials. Invest. New Drugs 5, 137-43.
6. Limo, J.T., Collins, W.T., Karcher, R.V., Hiles, R.A., Frick, S., Cibinic, J., Grieshaber, C.K. and Kastello, M.D. (1986) Preclinical studies of merbarone (NSC #336628) in beagle dogs: effect of dosing schedule on toxicity. Proc. Am. Ass. Canc. Res 27, 418.
7. Dimaggio, J., Warrell, R., Muindi, J, Stevens, Y.W., Lee, S.J., Lowenthal, D.A., Haines, I., Walsh, T.D., Baltzer, L., Yaldaei, S. and Young, C.W. (1990) Phase I clinical and pharmacological study of merbarone. Canc. Res. 50, 1151-5.
8. Clinical brochure for merbarone, prepared by the Division of cancer treatment, National Cancer Institute, October 1985.
9. Kraut, E.H., Grever, M.R., Staubas, A.E. and Malspeis, L. (1988) Phase 1 clinical trials of merbarone (NSC #336628). Proc. Am. Assoc. Canc. Res. 29, 191 (abstr. 760).
10. Look, K., Blessing, J., Adelson, M., Morris, M and Bookman, M. (1996) A phase II trial of merbarone (NSC #336628) in the treatment of recurrent epithelial ovarian carcinoma. Am. J. Clin. Oncol. (CCT) 19, 7-9.
11. Jones, D., Ajani, J., Winn, R.J., Daugherty, K.R., Levin, B. and Krakoff, I. (1993) A phase II study of merbarone in patients with adenocarcinoma of the pancreas. Cancer Invest 11(6), 667-9.
12. Look, K.Y., Blessing, J.A., Adelson, M.D., Morris, M. and Brookman, M. (1995) A phase 11 trial of merbarone (NSC #336628) as salvage therapy for squamous cell carcinoma of the cervix. Am. J. Clin. Oncol. 18, 441-3.